MX388751B - Compuestos de imidazo-piperidina fusionada como inhibidores de jak. - Google Patents
Compuestos de imidazo-piperidina fusionada como inhibidores de jak.Info
- Publication number
- MX388751B MX388751B MX2019012942A MX2019012942A MX388751B MX 388751 B MX388751 B MX 388751B MX 2019012942 A MX2019012942 A MX 2019012942A MX 2019012942 A MX2019012942 A MX 2019012942A MX 388751 B MX388751 B MX 388751B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- piperidine compounds
- jak inhibitors
- fused imidazo
- formula
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract 3
- AIAJYBLPGVBVSS-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-imidazo[4,5-b]pyridine Chemical class C1CCNC2=C1NC=N2 AIAJYBLPGVBVSS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Un compuesto de fórmula 1 (ver fórmula 1) o una sal farmacéuticamente aceptable del mismo, útil como inhibidor de JAK. La invención también provee formas cristalinas del compuesto, composiciones farmacéuticas que comprenden tal compuesto, métodos para usar el compuesto para tratar enfermedades susceptibles a un inhibidor de JAK, y procesos e intermediarios útiles para preparar el compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492574P | 2017-05-01 | 2017-05-01 | |
| PCT/US2018/030148 WO2018204238A1 (en) | 2017-05-01 | 2018-04-30 | Fused imidazo-piperidine jak inhibitor compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019012942A MX2019012942A (es) | 2019-12-16 |
| MX388751B true MX388751B (es) | 2025-03-20 |
Family
ID=62165730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012942A MX388751B (es) | 2017-05-01 | 2018-04-30 | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10493077B2 (es) |
| EP (1) | EP3601283B1 (es) |
| JP (1) | JP7098656B2 (es) |
| KR (1) | KR102550225B1 (es) |
| CN (1) | CN110573508B (es) |
| AR (1) | AR111495A1 (es) |
| AU (1) | AU2018261593B2 (es) |
| BR (1) | BR112019022648A2 (es) |
| CA (1) | CA3056283A1 (es) |
| CL (1) | CL2019003086A1 (es) |
| CO (1) | CO2019011809A2 (es) |
| CY (1) | CY1125051T1 (es) |
| DK (1) | DK3601283T3 (es) |
| EA (1) | EA201992601A1 (es) |
| ES (1) | ES2908756T3 (es) |
| HR (1) | HRP20220330T1 (es) |
| IL (1) | IL270231B2 (es) |
| LT (1) | LT3601283T (es) |
| MA (1) | MA47970B1 (es) |
| MD (1) | MD3601283T2 (es) |
| MX (1) | MX388751B (es) |
| NZ (1) | NZ757570A (es) |
| PH (1) | PH12019502264A1 (es) |
| PL (1) | PL3601283T3 (es) |
| PT (1) | PT3601283T (es) |
| RS (1) | RS62995B1 (es) |
| SG (1) | SG11201908604YA (es) |
| SI (1) | SI3601283T1 (es) |
| SM (1) | SMT202200079T1 (es) |
| TW (1) | TWI760486B (es) |
| UA (1) | UA124478C2 (es) |
| WO (1) | WO2018204238A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| AU2018231032B2 (en) | 2017-03-09 | 2021-08-19 | Theravance Biopharma R&D Ip, Llc | JAK inhibitors containing a 4-membered heterocyclic amide |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| KR102568333B1 (ko) | 2017-05-01 | 2023-08-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 저해제 화합물을 사용하는 치료 방법 |
| JP7383696B2 (ja) | 2018-09-04 | 2023-11-20 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤としての５員～７員の複素環アミド |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| EP3837253B1 (en) | 2018-09-04 | 2023-06-07 | Theravance Biopharma R&D IP, LLC | Process for preparing jak inhibitors and intermediates thereof |
| SG11202103042XA (en) | 2018-10-29 | 2021-04-29 | Theravance Biopharma R&D Ip Llc | 2-azabicyclo hexane compound as jak inhibitor |
| CN113784713A (zh) | 2019-01-11 | 2021-12-10 | 纳吉斯制药股份有限公司 | 白三烯合成抑制剂 |
| WO2020173400A1 (zh) * | 2019-02-25 | 2020-09-03 | 河南迈英诺医药科技有限公司 | Jak抑制剂化合物及其用途 |
| PH12021552130A1 (en) | 2019-03-05 | 2022-08-31 | Incyte Corp | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| TW202144346A (zh) * | 2020-03-18 | 2021-12-01 | 四川海思科製藥有限公司 | 一種吲唑衍生物及其在醫藥上的應用 |
| CN111620868B (zh) * | 2020-05-28 | 2021-08-31 | 爱斯特（成都）生物制药股份有限公司 | 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法 |
| TW202317550A (zh) * | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| CN114181055A (zh) * | 2021-12-21 | 2022-03-15 | 苏州楚凯药业有限公司 | 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法 |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| US20120029190A1 (en) | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| SMT201700581T1 (it) | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| ES2654051T3 (es) | 2013-12-05 | 2018-02-12 | Pfizer Inc. | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas |
| CN106459048A (zh) | 2014-05-14 | 2017-02-22 | 辉瑞公司 | 吡唑并吡啶类和吡唑并嘧啶类 |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| PT3371185T (pt) | 2015-11-03 | 2020-12-28 | Topivert Pharma Ltd | Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase |
| KR20180073687A (ko) | 2015-11-03 | 2018-07-02 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 호흡기 질환의 치료를 위한 jak 키나제 저해제 화합물 |
| EP3371184A1 (en) | 2015-11-03 | 2018-09-12 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| AU2018231032B2 (en) | 2017-03-09 | 2021-08-19 | Theravance Biopharma R&D Ip, Llc | JAK inhibitors containing a 4-membered heterocyclic amide |
| MX389014B (es) | 2017-05-01 | 2025-03-20 | Theravance Biopharma R&D Ip Llc | Formas cristalinas de un compuesto inhibidor de jak |
| KR102568333B1 (ko) | 2017-05-01 | 2023-08-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 저해제 화합물을 사용하는 치료 방법 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
-
2018
- 2018-04-27 AR ARP180101103A patent/AR111495A1/es unknown
- 2018-04-30 WO PCT/US2018/030148 patent/WO2018204238A1/en not_active Ceased
- 2018-04-30 MD MDE20200142T patent/MD3601283T2/ro not_active IP Right Cessation
- 2018-04-30 JP JP2019559297A patent/JP7098656B2/ja not_active Expired - Fee Related
- 2018-04-30 US US15/966,467 patent/US10493077B2/en active Active
- 2018-04-30 HR HRP20220330TT patent/HRP20220330T1/hr unknown
- 2018-04-30 BR BR112019022648A patent/BR112019022648A2/pt not_active IP Right Cessation
- 2018-04-30 ES ES18724754T patent/ES2908756T3/es active Active
- 2018-04-30 CN CN201880028413.7A patent/CN110573508B/zh not_active Expired - Fee Related
- 2018-04-30 TW TW107114647A patent/TWI760486B/zh not_active IP Right Cessation
- 2018-04-30 SI SI201830589T patent/SI3601283T1/sl unknown
- 2018-04-30 MA MA47970A patent/MA47970B1/fr unknown
- 2018-04-30 DK DK18724754.9T patent/DK3601283T3/da active
- 2018-04-30 PT PT187247549T patent/PT3601283T/pt unknown
- 2018-04-30 LT LTEPPCT/US2018/030148T patent/LT3601283T/lt unknown
- 2018-04-30 SG SG11201908604Y patent/SG11201908604YA/en unknown
- 2018-04-30 EA EA201992601A patent/EA201992601A1/ru unknown
- 2018-04-30 CA CA3056283A patent/CA3056283A1/en active Pending
- 2018-04-30 KR KR1020197035134A patent/KR102550225B1/ko active Active
- 2018-04-30 RS RS20220238A patent/RS62995B1/sr unknown
- 2018-04-30 NZ NZ757570A patent/NZ757570A/en not_active IP Right Cessation
- 2018-04-30 SM SM20220079T patent/SMT202200079T1/it unknown
- 2018-04-30 PL PL18724754T patent/PL3601283T3/pl unknown
- 2018-04-30 AU AU2018261593A patent/AU2018261593B2/en not_active Ceased
- 2018-04-30 MX MX2019012942A patent/MX388751B/es unknown
- 2018-04-30 UA UAA201911546A patent/UA124478C2/uk unknown
- 2018-04-30 EP EP18724754.9A patent/EP3601283B1/en active Active
-
2019
- 2019-09-30 PH PH12019502264A patent/PH12019502264A1/en unknown
- 2019-10-18 US US16/656,940 patent/US11160810B2/en not_active Expired - Fee Related
- 2019-10-24 CO CONC2019/0011809A patent/CO2019011809A2/es unknown
- 2019-10-28 CL CL2019003086A patent/CL2019003086A1/es unknown
- 2019-10-28 IL IL270231A patent/IL270231B2/en unknown
-
2021
- 2021-09-28 US US17/449,131 patent/US20220008428A1/en not_active Abandoned
-
2022
- 2022-03-09 CY CY20221100192T patent/CY1125051T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502264A1 (en) | Fused imidazo-piperidine jak inhibitors compound | |
| MX374605B (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria. | |
| MX388750B (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| PH12020500528A1 (en) | Pyrimidine compound as jak kinase inhibitor | |
| MX2020011774A (es) | Compuestos de naftiridina como inhibidores de quinasa jak. | |
| EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
| MX373154B (es) | Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1). | |
| MX2021004582A (es) | Compuesto 2-azabiciclo hexano inhibidor de jak. | |
| PH12021550388A1 (en) | Process for preparing jak inhibitors and intermediates thereof | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| EA201890752A1 (ru) | Способ получения противогрибковых соединений | |
| EA201792021A1 (ru) | Ингибитор jak | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| MX2018001699A (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1. | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| NZ742952A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| EA201790632A1 (ru) | 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса | |
| JOP20170164A1 (ar) | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |